Medpace (NASDAQ:MEDP) President Sells $14,436,197.10 in Stock

Medpace Holdings, Inc. (NASDAQ:MEDP) President Jesse Geiger sold 31,707 shares of the company’s stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total value of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Medpace Trading Down 1.8%

NASDAQ:MEDP opened at $452.51 on Friday. The stock has a 50-day moving average price of $509.09 and a 200 day moving average price of $538.29. The stock has a market capitalization of $12.84 billion, a P/E ratio of 29.58, a P/E/G ratio of 2.17 and a beta of 1.44. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $628.92.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings results on Monday, February 9th. The company reported $4.67 EPS for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The company had revenue of $708.45 million for the quarter, compared to analysts’ expectations of $689.53 million. During the same period in the previous year, the firm earned $3.67 EPS. The firm’s revenue was up 32.0% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, research analysts predict that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. NewEdge Advisors LLC lifted its position in Medpace by 22.1% during the first quarter. NewEdge Advisors LLC now owns 1,048 shares of the company’s stock valued at $319,000 after purchasing an additional 190 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Medpace by 3.8% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 81,817 shares of the company’s stock worth $24,929,000 after buying an additional 3,010 shares during the last quarter. Geneos Wealth Management Inc. increased its holdings in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares during the last quarter. Sivia Capital Partners LLC purchased a new stake in shares of Medpace during the 2nd quarter valued at about $296,000. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its position in shares of Medpace by 1.4% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,055 shares of the company’s stock valued at $1,900,000 after buying an additional 83 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on MEDP shares. Leerink Partners dropped their target price on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a research report on Wednesday, February 11th. Royal Bank Of Canada started coverage on shares of Medpace in a report on Tuesday, March 3rd. They issued an “outperform” rating and a $522.00 price target on the stock. Truist Financial decreased their price target on shares of Medpace from $555.00 to $539.00 and set a “hold” rating on the stock in a research note on Wednesday, February 11th. BMO Capital Markets reissued a “market perform” rating on shares of Medpace in a report on Wednesday, February 11th. Finally, Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective for the company in a research report on Friday, February 13th. Five equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Medpace has a consensus rating of “Hold” and a consensus target price of $486.67.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.